Bispecific antibody News and Research

RSS

Teclistamab shows promising results in heavily pretreated multiple myeloma

Teclistamab-cqyv (Tecvayli) led to clinically meaningful responses in patients with heavily pretreated multiple myeloma who would have been ineligible for the MajesTEC-1 trial, and identified a novel factor independently associated with outcomes.

12 Jul 2025

Innovative bispecific antibody targets LAG-3 to treat autoimmune diseases

Immune checkpoint pathways regulate T cell function and play pivotal roles in the treatment of both cancer and autoimmune diseases.

7 Jul 2025

Engineered protein silences harmful T cells in autoimmune disease

An engineered protein turns off the kind of immune cells most likely to damage tissue as part of Type-1 diabetes, hepatitis, multiple sclerosis, shows a new study in mice.

1 Jul 2025

Bispecific antibodies offer new hope for resistant NSCLC patients

As the leading cause of cancer-related death, lung cancer remains a noteworthy hazard to human health. NSCLC is the most prevalent subtype, accounting for nearly 85% of all lung cancer cases.

23 Jun 2025

Selective depletion of PD-1 positive lymphocytes using a novel bispecific killer engager

This new article publication from Acta Pharmaceutica Sinica B, discusses a bispecific killer engager for targeted depletion of PD-1 positive lymphocytes.

14 Apr 2025

Novel NK cell therapy shows strong response in lymphoma patients

A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a CD30/CD16A bispecific antibody, was safe and generated strong response rates for patients with refractory CD30-positive lymphomas, according to a new study from The University of Texas MD Anderson Cancer Center.

4 Apr 2025

Development of lymphoma following CAR-T cell therapy

Some forms of blood cancer, such as multiple myeloma and lymphoma, are malignant diseases that originate from immune cells, specifically lymphocytes.

22 Feb 2025

Harbour BioMed partners with Insilico to accelerate AI-powered antibody discovery

Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immunology and oncology, and Insilico Medicine ("Insilico"), a clinical stage generative artificial intelligence (AI)-driven biotechnology company, today announced a strategic collaboration to accelerate the discovery and development of innovative therapeutic antibodies, leveraging their respective technological strengths in antibody discovery and artificial intelligence.

21 Feb 2025

Distinct myeloid-derived suppressor cell populations fuel aggressive brain tumor growth

A type of aggressive, treatment-resistant brain tumor has a distinct population of immune cells that support its growth, according to new research led by investigators at the Johns Hopkins Kimmel Cancer Center Bloomberg~Kimmel Institute for Cancer Immunotherapy and the Johns Hopkins University School of Medicine.

7 Feb 2025

EZH2 inhibitors enhance effectiveness of cancer immunotherapies

An emerging class of anticancer drugs called EZH2 inhibitors may greatly enhance the potency of some cancer immunotherapies, according to a preclinical study led by Weill Cornell Medicine lymphoma researchers.

5 Dec 2024

New CAR T-cell therapy shows promise against aggressive HER2+ breast cancer

One-third of HER2-positive (HER2+) tumors express the P95HER2 protein, which associates with an aggressive form of breast cancer with a poorer prognosis. Investigators of the Vall d'Hebron Institute of Oncology's (VHIO) Growth Factors Group, in collaboration with researchers of the Cancer Research Program of Hospital del Mar Research Institute (HMRI), Barcelona, have developed novel chimeric antigen receptor (CAR) T-cell therapy that can produce a potent antitumor response against p95HER2-expressing cells.

19 Nov 2024

Researchers develop new antibody with potential to treat several types of cancer

Researchers at Uppsala University and KTH Royal Institute of Technology have developed a new form of precision medicine, an antibody, with the potential to treat several types of cancer.

11 Nov 2024

Global leaders gather at the NFCR Summit to drive breakthroughs in cancer care

The 2024 National Foundation for Cancer Research (NFCR) Global Summit and Award Ceremonies for Cancer Research & Entrepreneurship, co-hosted with the AIM-HI Accelerator Fund, convened the world's top experts across cancer research, biotech entrepreneurship, pharmaceuticals, investment, and patient advocacy.

28 Oct 2024

Advancements in antibody-drug conjugates transform cancer therapy

Antibody-drug conjugates (ADCs) have emerged as a promising approach in cancer therapy, offering a 'magic bullet' strategy that combines the precision of monoclonal antibodies with the potency of cytotoxic drugs.

22 Oct 2024

Cancer drug offers life-changing results for severe lupus patient

The team at Charité – Universitätsmedizin Berlin is astounded by the huge improvement seen in a female patient with severe systemic lupus erythematosus (SLE) after being treated with the cancer medication teclistamab. Not long ago, the 23-year-old was wheelchair-bound due to the autoimmune disease.

6 Sep 2024

MD Anderson and Summit Therapeutics partner to accelerate ivonescimab development

The University of Texas MD Anderson Cancer Center and Summit Therapeutics, Inc. today announced a strategic five-year collaboration agreement for the purpose of accelerating the development of ivonescimab.

25 Jul 2024

Wistar scientists develop Persistent Multivalent T Cell Engager for advanced kidney cancer

Advanced clear cell renal cell carcinoma (ccRCC) is a deadly form of kidney cancer with few treatment options; even with new immunotherapies, only around one in 10 patients ultimately survive.

4 Jun 2024

Novel combination treatment outperforms standard therapy in patients with EGFR NSCLC

The combination of the antibody amivantamab and lazertinib, a drug targeting EGFR, shows better clinical benefits compared to standard treatment in patients with advanced or metastatic non-small cell lung cancer with EGFR gene mutations who also present one of these poor prognosti markers: brain and/or liver metastases, p53 gene co-mutations, or the presence of circulating tumor DNA.

4 Jun 2024

New method enhances the efficacy of bispecific antibody therapies in treating solid tumors

Professor Seung-Woo Lee and PhD candidate Kun-Joo Lee from the Department of Life Sciences at Pohang University of Science and Technology (POSTECH), in collaboration with NeoImmuneTech Director Donghoon Choi and Professors Dae Hee Kim and Sun Shim Choi from Kangwon National University, have revealed a groundbreaking method to significantly enhance the efficacy of bispecific antibody therapies in treating solid tumors.

31 May 2024

Novel bispecific antibodies show promise against evolving SARS-CoV-2 variants

Researchers developed bispecific antibodies targeting both the N-terminal and receptor binding domains of SARS-CoV-2, demonstrating significant neutralization across various Omicron variants, suggesting potential for new COVID-19 treatments.

9 May 2024